Alle Storys
Folgen
Keine Story von Helsinn Healthcare SA mehr verpassen.

Helsinn Healthcare SA

HELSINN and PHARMASWISS announce a license agreement for ALOXI® in Baltic States, Slovenia and some Eastern European Countries

Lugano, Switzerland, and Ljulubiana (ots)

HELSINN HEALTHCARE
SA, a Swiss pharmaceutical group, and PHARMASWISS, a Pharmaceutical
company based in SLOVENIA, announce the signing of an agreement
granting PHARMASWISS the exclusive License and Distribution rights
for ALOXI® (Palonosetron hydrochloride) in Slovenia, Baltic states,
Croatia and other Ex-Yugoslavia countries.
ALOXI® is a strong and long acting antiemetic belonging to the
second generation of serotonin (5-HT3) antagonists, the leading class
for the prevention of nausea and vomiting induced by chemotherapy.
ALOXI" showed a great efficacy during the acute and delayed phase
after chemotherapy treatment vs other first generation 5-HT3s. The
product is already commercialized in USA where over a million uses
have been completed successfully. Last December the CHMP recommended
ALOXI" approval in Europe for the following indications:
  • the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and
  • the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
There is still a medical need among cancer patients and the
medical community to better prevent Nausea and Vomiting due to
chemotherapy treatments. International guidelines are always updated
with novelties to indicate the best treatments available for the
medical community and in 2004 the US National Comprehensive Cancer
Network (NCCN) guidelines indicated ALOXI® as the treatment of choice
for the prevention of acute and delayed nausea and vomiting due to
moderately emetogenic chemotherapies.
"Helsinn is glad to enter for the first time into an agreement
with PharmaSwiss", said Dr. Riccardo Braglia, Managing Director of
HELSINN HEALTHCARE SA. "PharmaSwiss has a Group of companies with a
significant record of successful marketing in ex Yugoslavian and
Baltic countries and a good expertise in Oncology. We look forward to
develop a long standing relationship specially within the Oncology
franchise".
"The in-licensing of ALOXI® from Helsinn for most of its
territories represents a significant development  for PharmaSwiss."
said Petr Nemec Chief Executive Officer. "For the first time,
PharmaSwiss will own rights to a novel, proprietary compound in one
of its core therapeutic areas, oncology. PharmaSwiss is exploring
other avenues of cooperation with Helsinn, particularly in the
therapeutic areas of oncological supportive care and clinical
research."
About Chemotherapy-Induced Nausea and Vomiting (CINV)
CINV is estimated to affect 85% of cancer patients undergoing
chemotherapy and can result in a delay or discontinuation of
chemotherapy treatments. The supportive care area is becoming of
paramount importance to help patients deal with adverse events of
anticancer therapies. With good supportive care drugs, cancer
patients are able to tolerate the anti-cancer treatment to a greater
extent, improving their chances of completing their treatment course
successfully with a better quality of life.
About ALOXI®
ALOXI® is a selective 5-HT3-receptor antagonist, developed for the
prevention of CINV, with a long half-life of 40 hours and at least 30
times higher receptor binding affinity than currently available
compounds. There have been over 2,800 patients treated during the
phase 3 clinical trials and over 1 million uses after its
commercialization in USA.  ALOXI® is effective in preventing both
acute and delayed CINV in patients receiving highly and moderately
emetogenic chemotherapy, the most common chemotherapy regimens used
in the treatment of cancer.  For more information about this product
please visit our website: www.palonosetron.net and www.aloxi.com.
About HELSINN HEALTHCARE
HELSINN HEALTHCARE SA is a privately owned pharmaceutical group
with headquarters in Switzerland and is the worldwide licensor of
ALOXI®.  HELSINN's core business is the licensing of pharmaceuticals
in niche therapeutic areas. The company's business strategy is to
in-license early-stage new chemical entities and complete their
development from the performance of pre-clinical/clinical studies and
CMC development to the attainment of market approvals in strategic
markets (U.S. and Europe). HELSINN's products are eventually
out-licensed to its marketing partners for distribution. The active
pharmaceutical ingredients and the finished dosage forms are
manufactured at HELSINN's cGMP facilities and supplied worldwide to
its customers. For more information about HELSINN, please visit
www.helsinn.com.
About PharmaSwiss
PharmaSwiss S.A. is a 60 million Euro pharmaceutical company,
headquartered in Zug, Switzerland. PharmaSwiss operates in 5 EU
countries (Estonia, Greece, Latvia, Lithuania and Slovenia) and in
six other Eastern European countries (Albania, Belarus, Bosnia,
Croatia, Macedonia and Serbia-Montenegro). With over 200 employees,
PharmaSwiss is an exclusive marketing agent and regional distributor
for six research-based multinationals -- Astellas (formerly Fujisawa
and Yamanouchi), Boots, Bristol-Myers Squibb, Ferring, Ipsen and
Wyeth
Contact person HELSINN: 
Rachid BenHamza, Ph.D.
Head Business Unit Oncology & Supportive Care
Phone   +41/91/985'21'21
E-Mail:  info-hhc@helsinn.com
Contact person PharmaSwiss:
R. Stuart Swanson
Area Manager, Member of Board
Phone   +386/31/693'200
E-Mail:  office@pharmaswiss.co.yu

Weitere Storys: Helsinn Healthcare SA
Weitere Storys: Helsinn Healthcare SA
  • 04.04.2005 – 08:00

    HELSINN new antiemetic drug ALOXI® receives marketing authorization in Europe

    Lugano Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, announced today that the European Commission has granted the marketing authorisation for their new drug ALOXI®. This announcement comes approximately three months after the CHMP's recommendation to approve ALOXI" for the prevention of acute nausea and vomiting associated with highly ...

  • 24.03.2005 – 08:46

    HELSINN AND CSC announce a license agreement for A ALOXI® in Central and Eeastern Europe

    LUGANO, SWITZERLAND, and VIENNA, AUSTRIA (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and CSC, a Pharmaceutical company based in AUSTRIA, announce the signing of an agreement granting CSC the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in Austria and other countries in Central and Eastern Europe. ALOXI® is ...

  • 28.02.2005 – 08:00

    Helsinn and Galencia announce a license agreement for Aloxi (Palonosetron) in Greece

    LUGANO, SWITZERLAND, and Athens, GREECE (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and GALENICA, a Pharmaceutical company based in Greece, announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in GREECE. ALOXI® is the second generation of serotonine (5-HT3) ...